Mr. Bloom's practice is focused on the representation of emerging and public life science companies and he serves as principal outside or general counsel to leading life science companies. In addition to day-to-day corporate counseling and strategic advice to his clients, he regularly handles a variety of major business transactions, including public offerings, mergers and acquisitions, venture capital financings and strategic collaborations and commercial transactions.
His recent client representations include work with:
- Ablynx NV in its $200 million initial public offering and €3.9 billion sale to Sanofi
- Alnylam Pharmaceuticals in its $450 million and $805 million public follow-on public offerings and in its strategic alliance and $700 million equity financing with Genzyme
- Aptinyx in its $118 million initial public offering, $65 million Series A financing and $70 million Series B financing
- Assembly Biosciences in its $69 million public follow-on offering
- BeiGene in its $158 million initial public offering and $200 million and $800 million follow-on public offerings
- Celyad SA in its $100 million initial public offering
- CRISPR Therapeutics AG in its joint venture with Bayer valued up to $335 million, $38 million additional Series B financing, $56 million initial public offering and $130 million follow-on offering
- Cullinan Oncology in its $150 million Series A financing
- DBV Technologies SA in its $92 million initial public offering
- Eidos Therapeutics in its $122 million initial public offering
- Esperion in its $70 million initial public offering and subsequent $97 million and $201 million follow-on public offerings
- Galapagos NV in its $275 million initial public offering, $337 million follow-on public offering and strategic collaboration with Gilead Sciences valued up to $2 billion
- Global Blood Therapeutics in its $120 million initial public offering and subsequent $120 million, $125 million and $100 million follow-on public offerings
- HotSpot Therapeutics in its Series A financing
- Inotek Pharmaceuticals in its $60 million initial public offering, $68.9 million and $50 million follow-on public offerings, and merger with Rocket Pharmaceuticals
- Jounce Therapeutics in its $104 million initial public offering, $56 million Series B and $47 million Series A financings
- Magenta Therapeutics in its $100 million initial public offering, $50 million Series B and Series A financings
- Mevion Medical Systems in connection with its $55 million equity and debt financing
- MyoKardia in its $46 million Series B financing and $54 million initial public offering and $143 million follow-on offering
- Neon Therapeutics in its $100 million initial public offering, $70 million Series B financing and $55 million of Series A financing
- Neos Therapeutics in its $75 million initial public offering
- Nimbus Therapeutics in its sale of Nimbus Apollo to Gilead Sciences valued up to $1.2 billion, collaborations with Monsanto and Shire Plc and its $43 million Series B financing
- Ocata Therapeutics in its $379 million sale to Astellas Pharma
- Orchard Therapeutics in its $225 million initial public offering
- ProQR Therapeutics B.V. in its $97.5 million initial public offering and $29 million public follow-on offering
- Proteostasis Therapeutics in its $50 million initial public offering, $65 million and $40 million follow-on public offerings
- Quartet Medicine in its $595 million strategic collaboration with Merck
- RainDance Technologies in its sale to Bio-Rad Laboratories
- Relay Therapeutics in its $57 million Series A financing and $63 million Series B financing
- resTORbio in its $85 million initial public offering
- Rheos Medicines in its $60 million Series A financing
- SAGE Therapeutics in its $90 million initial public offering and subsequent $138 million, $150 million, $175 million, $345 million and $575 million follow-on public offerings
- Tango Therapeutics in its $55 million Series A financing
- TCR2 Therapeutics in its $44.5 million Series A financing and $125 million Series B financing
- Voyager Therapeutics in its strategic collaboration with Genzyme for $100 million upfront and up to $745 million in milestone payments, and in its $45 million Series A financing, $60 million Series B financing and $70 million initial public offering
- Warp Drive Bio in its innovative strategic partnership with Sanofi
- Xeris Pharmaceuticals in its $98 million initial public offering
- Zafgen in its $96 million initial public offering and subsequent $137 million follow-on public offering
- Representation of underwriters in connection with public offerings for AC Immune, Edge Therapeutics, Flexion Therapeutics, InflaRX, Intrexon Corporation, NPS Pharmaceuticals, Ovid Therapeutics, Reata Pharmaceuticals, Roka Biosciences, Tokai Pharmaceuticals and Regulus Therapeutics
- Representation of leading venture firms including Third Rock Ventures, Atlas Venture, Versant Ventures and 5AM Ventures
Professional Activities
Mr. Bloom is a member of the American, Massachusetts and Boston Bar Associations.
Professional Experience
Prior to joining Goodwin, Mr. Bloom was a partner at Testa, Hurwitz & Thibeault in Boston, where he was a member of the Business Practice Group and co-chair of its Life Sciences Practice.
